Status:
COMPLETED
Accuracy of Cardiac Wearables Devices to Detect Atrial Fibrillation
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Atrial Fibrillation (AF)
Eligibility:
All Genders
18+ years
Brief Summary
Atrial fibrillation (AF) is the most common cardiac arrhythmia. This study is to assess the heart rhythm device accuracy of five cardiac wearable devices (Apple Watch, Kardia Mobile/Kardia Mobile 6L, ...
Eligibility Criteria
Inclusion
- All consecutive patients undergoing electrophysiological study, pacemaker or implantable defibrillator (ICD) implantation or electric cardioversion at the University Hospital Basel are eligible for study participation and will be asked to participate
Exclusion
- Use of a radial artery graft for coronary artery bypass grafting
- Tattoos located on the skin of the wrist or forearm where wearable device will be placed
- Patients receiving hemodialysis through arteriovenous fistula in the upper extremities
- Patients with inability to communicate and comply with all study requirements
- Patients who refused to participate in the trial
Key Trial Info
Start Date :
April 6 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2024
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT04809922
Start Date
April 6 2021
End Date
February 28 2024
Last Update
March 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiology, University Hospital Basel
Basel, Switzerland, 4031